Short name: GN-1140, chemical compound: Gd-DTPA-DeA, central moiety: Gd, phase: II
Gd-DTPA-DeA [Welfide Corp., Osaka, Japan], a paramagnetic MR contrast agent with hepatobiliary excretion is under development for liver imaging. This hydrophilic gadolinium chelate is a derivative of Gd-DTPA.

Short name: Gd-BOPTA, generic name: Gadobenate dimeglumine
A paramagnetic MRI contrast agent (small molecular weight Gd-chelate) with 0.5 and 0.25 molar concentration.
The albumin-mediated relaxation enhancement may result in advantages for Gd-BOPTA over Gd-DTPA and other gadolinium agents in poorly vascularized, small, or lesions with low enhancement and in tumors with high concentrations of albumin. The substance is excreted partly by the kidneys (75-90%), partly by the biliary system (10-25%). The uptake in the liver is about 5% in humans. It is bolus injectable.

See Contrast Agents and MultiHance®.

Short name: Gd-DO3A-butriol, generic name: Gadobutrol
A paramagnetic contrast agent with 0.5 and 1.0 molar concentration.

See Contrast Agents and Gadovist®.

Short name: Gd-DTPA-BMA, generic name: Gadodiamide, chemical compound: Gd-diethylenetriaminepentaacetate-bis(methylamide), central moiety: Gd
A paramagnetic MRI contrast agent (nonionic) with a small molecular weight linear chelate. Due to the linkage of two DTPA molecules through amide bonds the molecule is uncharged and has a low osmolality. The substance is excreted almost exclusively by the kidneys.

See also Nonionic Intravenous Contrast Agents and Omniscan®.

(Gadolite® oral Suspension) An oral paramagnetic MRI contrast agent to enhance delineation of the bowel. Zeolites are hydrated aluminosilicates with large holes that can provide a temporary home for guest molecules like gadolinium. Zeolites modified with Gd (III) are effective positive MRI contrast agents for gastrointestinal application.